Windon Energy Group AB (”Windon” eller ”bolaget”) meddelade den 28 september år 2023 att bolaget exp...
Redeye updates its estimates ahead of the Q3 report (due 27 October) with a small downward adjustmen...
Redeye returns with a more in-depth take on the discontinuation of Cranial.
Bolaget har spännande prospektering på gång, vilket vid ett lyckosamt utförande kan ge ett bra värde...
Strategiskifte OssDsign kommer nu att fokusera enbart på kommersialiseringen av OssDsign Catalyst i ...
Value accretive shift in strategy Directed share issue of SEK 150m Fair value range up to SEK 9-15 (...
Cantargia will present new clinical data at the AACR 2023 relating to IL1RAP in pancreatic cancer, t...
Redeye is encouraged by the publication of the clinical results from a study at the University Child...
Redeye updates on EG7 following the new strategy that was announced in connection with the company’s...
Redeye is once again positively surprised that Arise will see further revenue recognition and receiv...
Q3 report due 7 October Q3e net sales SEK 426m, EBITA SEK 52m Share trading at 6.
• Q3 report due 25 Oct • Q3'23e net sales SEK 167m, EBITA SEK 22m • Share trading at 6x Factset cons...
• Focus on orthobiologics going forward • New financial targets and rights issue • Expected to be ac...
PolarCool meddelade idag den 26 september att bolaget har förlängt avtalet med HC Davos, vilket är e...
• Reserves SEK 4.4m after Paygoo partner files for bankruptcy • Consensus 2023e EBITDA affected by ~...
Redeye ups its near-term sales estimates for Ortoma following its USD8.
On top of the EUR 30m cost-savings programme launched in January, Fiskars announced on 13 September ...
Redeye considers the partnership with Elon Group AB (Elon) to be a strategically sound move that ali...
NoHo acquires three restaurant in Oslo, Norway. Aggregated purchase price for all businesses is EUR ...
Redeye ser positivt på morgonens besked att Leqembi har godkänts i Japan och därmed att BioArctic få...
